According to our experimental results, topical fluoxetine reduced TRPV3-driven inflammation and pruritus with an efficacy comparable to that of dexamethasone, suggesting that fluoxetine could be used as a steroid-sparing agent for conditions such as atopic dermatitis. This evidence concerns the gene TRPV3 and atopic eczema.